Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.2
2.2
Journals
Diabetology
Special Issues
Diabetes Technology Trends: Latest Innovations and Future Perspectives
share announcement

Diabetes Technology Trends: Latest Innovations and Future Perspectives

A special issue of Diabetology (ISSN 2673-4540).

Deadline for manuscript submissions: 20 October 2026 | Viewed by 1416

Special Issue Editors

Dr. Sandro Gentile

E-Mail Website
Guest Editor
1. Internal Medicine, Department of Precision Medicine, Vanvitelli University of Naples, Naples, Italy
2. Research Department, Nefrocenter Research Network, Torre del Greco, Italy
Interests: diabetes; metabolism; endocrinology; hypertension; metabolic diseases; blood pressure; atherosclerosis; nutrition; internal medicines; insulin resistance; lipid metabolism; nutraceuticals; medical aerospace
Special Issues, Collections and Topics in MDPI journals
Dr. Felice Strollo

E-Mail Website
Guest Editor
Endocrinology and Diabetes Department, IRCCS, San Raffaele Pisana, 00163 Rome, Italy
Interests: diabetes; metabolism; endocrinology; hypertension; metabolic diseases; blood pressure; atherosclerosis; nutrition; internal medicines; insulin resistance; lipid metabolism; nutraceuticals; medical aerospace
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As Guest Editor of a Diabetology Special Issue, titled “Diabetes Technology Trends: Latest Innovations and Future Perspectives”, I invite you to submit an original research article, systematic review, narrative review, or communication on this topic. 

Diabetology (ISSN 2673-4540) is an international, open access journal. 

In this Special Issue of Diabetology, we invite researchers to submit their works on the development, testing, and implementation of a culture of technology applied to diabetes as a tool to achieve optimal management and improve the quality of life for people living with diabetes. Furthermore, it is essential to note that in many professional fields, technology is becoming the key to achieving excellent results and overcoming barriers, as demonstrated by the numerous professional athletes who have won Olympic medals and other accolades.

The official deadline for paper submission is 20 April 2026, and instructions on how to proceed with writing will be available on a dedicated webpage. 

Research areas may include (but are not limited to) the following:

  • Technological innovation;
  • Insulin pumps;
  • Glucose sensors;
  • Integrated intelligent systems;
  • Devices;
  • Pharmaceutical technologies;
  • Artificial intelligence applications;
  • Innovation in communication.

Dr. Sandro Gentile
Dr. Felice Strollo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diabetology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • insulin therapy
  • technological innovation
  • insulin pump
  • glucose sensor
  • integrated intelligent systems
  • devices and technology
  • pharmaceutical technologies
  • artificial intelligence applications
  • innovation in communications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1742 KB  
Article
Enhancing Insulin Therapy Adherence Through Technology: Which Needles Do People with Diabetes Prefer?
by Sandro Gentile, Raffaella Fiorentino, Maddalena Lettieri, Giuseppina Guarino, Giampiero Marino, Elisabetta Tommasi, Vera Frison, Ersilia Satta, Maria Chiarello, Giuseppe Caccavale, Emilia Masuccio and Felice Strollo
Diabetology 2026, 7(3), 56; https://doi.org/10.3390/diabetology7030056 - 9 Mar 2026
Viewed by 979
Abstract
Background: Despite major advances in insulin formulations and delivery systems since 1921, many people with diabetes (PwDs) still fail to achieve recommended glycemic targets. Common reasons include inadequate education, injection errors, and poor adherence due to factors such as needle phobia and pain. [...] Read more.
Background: Despite major advances in insulin formulations and delivery systems since 1921, many people with diabetes (PwDs) still fail to achieve recommended glycemic targets. Common reasons include inadequate education, injection errors, and poor adherence due to factors such as needle phobia and pain. Recognition of these barriers has driven the development of improved injection systems, particularly thinner and shorter needles. An experimental study previously identified the Pic Insupen 34 G 3.5 mm needle as high performing. We therefore conducted an observational study to assess its acceptability directly among PwDs. Methods: This multicentre, open-label, real-world study enrolled 300 insulin-treated PwDs who compared their usual pen needle (30–33 G) with the new 34 G × 3.5 mm needle over two two-week periods. The primary outcome was perceived puncture pain. Results: Participants overwhelmingly preferred the 34 G needle, based on the following findings: Pain perception: 62% of 34 G users reported minimal or no pain, compared with only 8% using their previous needle. Conversely, 22% of participants reported the highest pain score with their old needle, compared with just 5% using the 34 G. Ease of use: 77% rated the 34 G needle at the highest level of ease of use, compared with 20% for their previous needle. Complications: The 34 G needle was linked to significantly fewer hypo-/hyperglycemic episodes and local skin complications such as bruising or irritation. Eighty per cent reported no glycemic fluctuations while using the 34 G needle. Robustness: Ninety-four per cent of PwDs never observed the 34 G needle bending during use, compared with 64% using their previous needle, confirming greater robustness despite its thinner profile. Conclusions: The Insupen® 34 G × 3.5 mm needle substantially reduces puncture pain and improves the overall manageability of insulin injections. Its innovative design—combining reduced thickness with optimised tip geometry—is associated with fewer complications and enhanced injection performance. Because reduced pain and ease of use are critical for improving adherence to insulin therapy, the features of the 34 G needle should inform future prescribing decisions. Full article
(This article belongs to the Special Issue Diabetes Technology Trends: Latest Innovations and Future Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop